• “Face to study of weekly Topotecan in recurrent of metastatic cervical cancer: a Geico Study” M.J. Rubio, A. Santaballa, Y. García, A. González, I. Bover, E. Calvo, J.A. Contreras, J.M. Del Campo, A. de Juan, A. Poveda. Journal Clinical Of Oncology 26: 2008 (May 20 suppl.:abst.5591)

• “Feasibility and Toxicity of modified outpatients regimen of intraperitoneal chemotherapy (IP) in optimally debulked stage III ovarian cancer patients”. A. Oaknin, A. Cervantes, J. García, Y. García. A. de Juan, S. Catot, X. Pérez, J.M. Campo, A. González, A. Poveda. 12th Biennal Meeting International Gynecologic Society-IGCS. Oct. 2008:406

• “Early CA-125 response pattern in patients with recurrent ovarian cancer treated with pegilated liposomal doxorrubicin (PLD). A. Oaknin, P. Barretina, L. Jiménez, X. Pérez, M. Velasco, M. Alsina, B. Pardo, J. Brunet, J.R.Germà, M. Beltran. Annals of Oncology, vol. 19 supp.8; 33rd. ESMO congress, Sept. 2008: 680P.

• “Early stages (I-IIA) epithelial ovarian cancer (EOC):Preliminary data of the proxpective register of the Spanish Group on Research of Ovarian Cancer (GEICO). N. Ruíz, JM del Campo, E. Calvo, A. Santaballa, C. Churruca, A. herrero, A. casado, N. Lainez, A. Poveda, B. Ojeda. ESMO congress 2008

• “Human papillomavirus and cervical cancer prevention”. A. Oaknin,P. Barretina.Clinical and Translational Oncology (2008)10: 804-811.

• “Actualización en cáncer ginecológico 2007: Cáncer de Ovario y de cérvix”A. Poveda, A. Casado, MJ. Rubio, A. Oaknin, A. Santaballa, C. Mendiola, A. González, JM del Campo, J. Cueva, J. Casinello. Mfar, S.L. 2008

• “¿Cáncer de Cérvix? 100 preguntas más frecuentes”. MJ. Rubio, A.Oaknin, A. Poveda. Edimsa, 2008
“25 preguntas más frecuentes en Oncología: Cáncer de Ovario” A. Oaknin. Publicaciones Permanyer 2008

•  “Update in the management of ovarian and cervical cancer” A. Poveda, R. Salazar,J.M. Campo, C.Mendiola,J. Casinello, B. Ojeda, J.A.Arranz, A. Oaknin, J. García Foncillas, M.J. Rubio and A. González M. Clinical and Translational Oncology (2007)9;441-451.

•  “Randomized phase II trial of Carboplatin versus Paclitaxel and Carboplatin in platinum sensitive recurrent advanced ovarian carcinoma”a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ, Moyano A, Cervantes A. Ann Oncol 2005; 16: 749 – 755

• “Ovarian cancer treatment: what is new?”A. Poveda. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50.

• “Is combination chemotherapy superior to single-agent chemotherapy in second line treatment?A. Gonzalez-Martin; Geico Group. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:185-91.

• “Topotecan in platinum resistant advanced ovarian cancer patients”. Evaluation of activity and prognostic factors of response: preliminary results. A study of Spanish Group for Research on Ovarian Cancer (GEICO). V.Soriano, C.Balañá, M.A.Izquierdo, A.Herrero, J.M. del Campo, A.Cervantes, A.Poveda, I.Bover, A.Casado, A.Arcusa, B.Ojeda, T.Massuti, I.Tusquets, I.Álvarez, E.Calvo. Ann Oncol.2000.vol II (suppl.4):85

• “A combination of a fixed dose of Carboplatin plus Paclitaxel and Adriamycin in first-line therapy for advanced ovarian cancer and subopimal surgical cytorreduction “A phase I trial of the Spanish Group for Ovarian Cancer Research and treatment (GEICO). A.Cervantes, A.Poveda, A.González, B.Massuti, C.Balañá, A.Insa. Eur.J.Cancer 1999; 35(Suppl 4): S239.

• “Dose-Escalated Paclitaxel in 1-Hour Infusion with a Fixed Dose of Cisplatin in Previously Untreated Advanced Ovarian Cancer”A Phase II Trial of the Spanish Group for Ovarian Cancer. A.Cervantes, C.Mendiola, JM del Campo, B.Massuti, A.Casado, A.Escobedo, A.Moyano, B.Ojeda, A.Poveda and D.Benito. Seminars in Oncology 1997; vol 24, Nº 5 (Suppl 15) : S15-S43.

• “A Phase II Trial of High Dose Single Agent Paclitaxel as First Line Therapy in Advanced Ovarian Cancer “A. Cervantes, A. Escobedo, JM del Campo, A. Poveda, MD Benito, JR Germá-Lluch. Annals of Oncology 1996; 7 (suppl 5): 76.